BPC-157

Mechanism of action

BPC-157 is a stable synthetic pentadecapeptide comprising the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, derived from a larger cytoprotective protein isolated from human gastric juice. Its unique stability in gastric acid, pepsin, and pancreatic juice distinguishes it from most peptide research compounds and facilitates both systemic and local activity following oral administration in rodent models. The most thoroughly documented molecular mechanism involves upregulation of growth-hormone receptor (GHR) expression in tendon fibroblasts, an effect that potentiates GH-dependent angiogenic and proliferative cascades without directly elevating circulating growth-hormone or IGF-1 concentrations. In parallel, BPC-157 robustly modulates the nitric-oxide (NO) system: it attenuates the tissue damage driven by L-NAME (an NOS inhibitor) and blocks the vascular disruption caused by L-arginine overdose, demonstrating bidirectional stabilisation of NO homeostasis. This nitric-oxide axis also explains reported blood-pressure normalising effects in hypertensive rat models. Angiogenesis promotion is a second central mechanism. Hsieh and colleagues demonstrated that BPC-157 increases VEGFR2 internalisation and downstream Akt-eNOS phosphorylation in cultured endothelial cells, resulting in enhanced tube formation. In injured tissue, this 'vessel-rescuing' effect — a term coined by the Sikiric group — appears to underpin the accelerated re-vascularisation observed following Achilles tendon transection, bowel anastomosis, and traumatic muscle injury in rodents. VEGF expression is upregulated in granulation tissue of BPC-157-treated wounds, while parallel reductions in pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) dampen the destructive phase of the healing response. Gastrointestinal protection involves direct mucosal cytoprotection, stimulation of epithelial migration, and restoration of mesenteric blood flow following ischaemia-reperfusion injury. In models of NSAID-induced enteropathy, BPC-157 maintains intestinal tight-junction protein expression (claudin-4, occludin) and reduces bacterial translocation. In the central nervous system, independently conducted studies have observed neuroprotective effects in excitotoxic models, possibly mediated through dopaminergic modulation — an area of active, if preliminary, investigation. A particularly noteworthy feature of the pre-clinical literature is the apparent route-independence of BPC-157 effects across a wide range of injury models: parenteral, oral, and topical administrations have each produced statistically significant results in relevant studies, which is unusual for a peptide of this molecular weight and is attributed to its atypical stability in biological fluids.

BPC-157 accelerated Achilles tendon healing and restored vascular integrity in rodents via VEGFR2-Akt-eNOS signalling — effects observed whether the compound was given intraperitoneally, orally, or topically.

— Notable finding

Research history

BPC-157 was first characterised and synthesised in the early 1990s by Predrag Sikiric and colleagues at the University of Zagreb, Faculty of Medicine, as part of a programme to identify the bioactive sequences within human gastric juice protective proteins. The compound was initially assigned the development code PL 14736 by its earliest commercial licensees and entered pre-clinical investigation as a candidate for inflammatory bowel disease and peptic ulcer management. Despite strong pre-clinical results across gastrointestinal, tendon, ligament, muscle, vascular, and neurological models, clinical development has not advanced to Phase III completion. The primary published reason is the challenge of designing human trials that adequately capture outcomes spanning multiple tissue types — no single indication has attracted sufficient regulatory-pharmaceutical investment to advance. As of the mid-2020s the compound has accumulated more than 200 indexed animal and cell-culture studies, making it one of the most extensively studied synthetic peptides outside the mainstream pharmaceutical pipeline. The Zagreb group led by Sikiric remains the dominant contributor to the literature, a concentration that has attracted methodological critique from commentators who note the absence of independent large-scale replication. Some investigators at other European institutions have confirmed sub-sets of the original findings, particularly the angiogenic and NO-modulating properties, but the overall evidentiary base remains pre-clinical. Efforts to progress BPC-157 towards orphan-drug designation for Crohn's disease and anastomotic-leak prevention have been discussed in conference presentations but have not resulted in registered human trials as of the date of this review.

Reported research-model dose ranges

The ranges below are taken from published pre-clinical literature. They do not constitute a dosing recommendation for human use.

Summarised studies

Safety profile

Across more than two decades of rodent toxicology, BPC-157 has consistently demonstrated a wide therapeutic window. Acute lethal-dose studies have not identified an LD50 in mice or rats at doses many orders of magnitude above the typical research range. Chronic administration studies in rodents have not produced organ-level histopathological changes in liver, kidney, or gastrointestinal tissue at relevant doses. Long-term human safety data do not exist, and this is the critical caveat for any research-context interpretation. Oncogenicity studies have not been systematically conducted; the peptide's pro-angiogenic properties theoretically warrant careful consideration in individuals with pre-existing neoplastic conditions, though no tumour-promotion signal has been reported in the available animal literature. Reproductive and developmental toxicity has not been formally assessed. Immunogenicity is considered low given the peptide's short length, but formal immunogenicity studies have not been published. As with all synthetic peptide research preparations, the dominant practical safety variables are the quality of the synthesis, sterility of the final product, endotoxin (LAL test) result, and accurate measurement of concentration. Contamination with truncation fragments or racemised amino acids may produce spurious biological effects that confound interpretation. Researchers should source materials with certificates of analysis detailing HPLC purity (>98%), mass-spectrometry confirmation of sequence, and endotoxin levels below 1 EU/mg.

UK regulatory status

BPC-157 is not authorised as a medicine by the UK Medicines and Healthcare products Regulatory Agency (MHRA) and does not hold a product licence, marketing authorisation, or investigational medicinal product (IMP) designation in Great Britain or Northern Ireland. It may not lawfully be administered to, or supplied for human use to, any person within the United Kingdom outside an authorised clinical trial. On the international anti-doping front, the World Anti-Doping Agency (WADA) includes BPC-157 on the Prohibited List under category S0 (Non-Approved Substances), which applies to any substance not currently approved by any governmental regulatory authority for human therapeutic use. This prohibition applies both in-competition and out-of-competition. Athletes who test positive for BPC-157 face sanction regardless of route of administration or purported intent. Possession of BPC-157 as a research chemical for legitimate in-vitro laboratory use is not restricted under UK medicines law, provided the compound is not presented, sold, or supplied as a medicine. Researchers holding the compound in a laboratory context should retain documentation of research purpose and ensure storage and handling conditions meet institutional biosafety standards. No specific UK enforcement actions relating to BPC-157 are recorded in the public domain at the time of writing.

Frequently asked questions